GLOBAL HEALTH VENTURES - Latest News

Global Health Ventures Signs Agreement With Vida Pharma for Manufacturing of Sexual Enhancement Drug

VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--May 11, 2009 -- Global Health Ventures Inc. (OTC BB:GHLV.OB - News) announced today that it has signed an agreement with Vida Pharma of Montreal, Canada, a contract manufacturer of cGMP pharmaceutical drugs and nutritional supplements. Under the agreement, Vida will develop a manufacturing process and supply clinical grade cGMP material to enable Global Health Ventures' (the "Company") prospective drug in human clinical trials. Global Health Ventures is developing a new sexual enhancement drug for men. Vida Pharma is a suitable partner for the Company's drug manufacturing as they have considerable experience in manufacturing of human therapeutics.

About GHL-901

GHL-901 is a new formulation of an existing sexual enhancement drug marketed throughout the world. The current formulation of the drug carries a number of side effects, and has a slow mode of action. Global Health Ventures has developed a new proprietary formulation which appears to have less side effects and an extremely fast mode of action. The sexual enhancement market is over $5 billion annually, and growing tremendously every year. There is currently an open market for a new drug with fewer side effects, and a quicker mode of action. Our product, GHL-901, we believe to have both properties of fast acting and less side effects. With the current agreement, we are poised to manufacture our product rapidly and carry out the necessary testing prior to entering into commercialization.

About Global Health Ventures
Global Health Ventures Inc. is a 'Healthcare Technology Merchant Bank', and is in the business of acquiring and licensing outstanding healthcare technologies for further development, and re-licensing to major pharmaceutical companies. While venture capital and private equity firms tend to be investment-oriented, the Company licenses or buys the promising technology from biotech companies with insufficient resources, or lack of appropriate management for further development. GHV develops the technologies to mid-stage Phase III clinical trials and then sells or out-licenses to major pharmaceutical, biotechnology or speciality Pharma worldwide for upfront fees, milestones, and royalties.

Safe Harbour Statement

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing. Further, the risks involve the ability of the Company to accelerate the development, and the ability to out-license the products as well as, the ability to raise sufficient funds for the development. Specifically, the risks and uncertainties that could affect the success of the Company include risks associated with clinical developments, the ability of the Company to continue to raise capital to fund its operations and the capital requirements of the licensed-in products. Investors should also review the risk factors listed in the Company's filings with the Securities and Exchange Commission.

Media Contact:

Global Health Ventures Inc.

Director, Investor Relations
Global Health Ventures
Tel: 604-324-4844
Fax: 604-324-4845
Email: contact@globalhvs.com